Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Steven H Lam"'
Autor:
Lin-Hong Shi, Steven H. Lam, Ho So, Crystal Y. Chan, Tena K. Li, Cheuk-Chun Szeto, Lai-Shan Tam
Publikováno v:
Clinical and Experimental Hypertension, Vol 45, Iss 1 (2023)
Objectives To elucidate the risk factors for the development of incident hypertension (IHT) in patients with axial spondyloarthritis (axSpA). Methods We conducted a retrospective cohort study in axSpA patients who were recruited from 2001 to 2019 fro
Externí odkaz:
https://doaj.org/article/2f37787e8699472cb6ad9d2664c0b2cf
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 14 (2022)
Background: Axial spondyloarthritis (axSpA) patients are at higher risk of cardiovascular (CV) disease (CVD) than the general population, partly due to consequences of inflammation or its treatment. But relationship between inflammation in axSpA and
Externí odkaz:
https://doaj.org/article/1f3566099870439bb0f0bd0fceb06e2a
Autor:
Steven H. Lam, Ho So, Isaac T. Cheng, Edmund K. Li, Priscilla Wong, Tena K. Li, Alex Pui-Wai Lee, Lai-Shan Tam
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 13 (2021)
Aims: Psoriatic arthritis (PsA) is associated with accelerated atherosclerosis due to underlying inflammation. Whether inflammatory burden and drugs used to suppress inflammation over time are associated with cardiovascular (CV) events remained uncle
Externí odkaz:
https://doaj.org/article/3d6007671c66499c881e4b7fabd467e5
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94fff45fedb990a0073ddb2636097623
https://doi.org/10.2139/ssrn.4277522
https://doi.org/10.2139/ssrn.4277522
Autor:
Tsz On Lam, Isaac T Cheng, Steven H Lam, Chi Chiu Mok, Carmen T Ho, Tommy T Cheung, Virginia W Lao, Hin Ting Pang, Chi Hung To, Cheuk Wan Yim, Alexandra Ng, Kitty Y Kwok, Ka Lai Lee, Shirley K Ying, Man Choi Wan, Jolly M Lee, Lai-Shan Tam
Publikováno v:
SSRN Electronic Journal.
Objectives This study explored whether the excess cardiovascular (CV) disease (CVD) risk in RA could be ameliorated by suppression of inflammation using a treat-to-target (T2T) approach. We compared the CV event (CVE) incidence among ERA patients man
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9233462a138a3ee15a33aada09f84149
https://doi.org/10.2139/ssrn.4258963
https://doi.org/10.2139/ssrn.4258963